Symbols / TPST
TPST Chart
About
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.27M |
| Enterprise Value | 11.95M | Income | -36.05M | Sales | — |
| Book/sh | 1.43 | Cash/sh | 1.69 | Dividend Yield | — |
| Payout | 0.00% | Employees | 24 | IPO | — |
| P/E | — | Forward P/E | -0.90 | PEG | — |
| P/S | — | P/B | 1.74 | P/C | — |
| EV/EBITDA | -0.33 | EV/Sales | — | Quick Ratio | 2.13 |
| Current Ratio | 2.30 | Debt/Eq | 132.45 | LT Debt/Eq | — |
| EPS (ttm) | -9.73 | EPS next Y | -2.76 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-26 | ROA | -89.32% |
| ROE | -4.05% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 4.93M |
| Shs Float | 2.84M | Short Float | 2.94% | Short Ratio | 1.66 |
| Short Interest | — | 52W High | 12.23 | 52W Low | 2.16 |
| Beta | -2.24 | Avg Volume | 131.62K | Volume | 23.49K |
| Target Price | $11.00 | Recom | None | Prev Close | $2.40 |
| Price | $2.49 | Change | 3.75% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$11.00
Mean price target
2. Current target
$2.49
Latest analyst target
3. DCF / Fair value
$-74.31
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.49
Low
$11.00
High
$11.00
Mean
$11.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-22 | up | HC Wainwright & Co. | Neutral → Buy | $11 |
| 2025-04-10 | down | Scotiabank | Sector Outperform → Sector Perform | $9 |
| 2025-04-10 | down | HC Wainwright & Co. | Buy → Neutral | $16 |
| 2025-03-28 | main | Scotiabank | Sector Outperform → Sector Outperform | $7 |
| 2025-03-28 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-11-13 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2024-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-06-21 | reit | Piper Sandler | Overweight → Overweight | $8 |
| 2024-06-20 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-03-14 | init | Scotiabank | — → Sector Outperform | $13 |
| 2024-03-13 | init | Scotiabank | — → Sector Outperform | $13 |
| 2024-03-12 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-02-08 | init | Jefferies | — → Buy | $15 |
| 2023-10-11 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
- Tempest Therapeutics (TPST) Price Target Increased by 22.22% to 11.22 - Nasdaq Wed, 04 Feb 2026 08
- Partner-funded China trials anchor Tempest’s new CAR-T push - Stock Titan Wed, 11 Feb 2026 08
- Tempest Therapeutics Closes All-Stock Transaction to Acquire Next-Generation CAR-T Assets and Appoints Matt Angel as CEO - Quiver Quantitative Wed, 04 Feb 2026 08
- TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - Stocktwits Wed, 19 Nov 2025 08
- Tempest Therapeutics stock falls after $4.25 million direct offering - Investing.com ue, 25 Nov 2025 08
- Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO - Fierce Biotech Wed, 19 Nov 2025 08
- Why Tempest Therapeutics (TPST) Stock Is Down 45% Today - Benzinga Wed, 19 Nov 2025 08
- Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 - Yahoo Finance Wed, 19 Nov 2025 08
- Tempest gains CAR Ts for 65% of the company; stock drops - BioWorld MedTech Wed, 19 Nov 2025 08
- Tempest Therapeutics Reports Q3 2025 Financial Results and Strategic Update on Clinical Developments - Quiver Quantitative Wed, 05 Nov 2025 08
- Tempest Therapeutics stock plunges after all-stock acquisition - Investing.com Wed, 19 Nov 2025 08
- Tempest Announces $4.6 Million Registered Direct Offering of Common Stock - Yahoo Finance Wed, 11 Jun 2025 07
- Cancer drug developer Tempest to hand out 1:1 stock warrants - Stock Titan ue, 20 Jan 2026 08
- Tempest Therapeutics to acquire Factor Bioscience’s CAR-T programs - Investing.com Wed, 19 Nov 2025 08
- Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition - FinancialContent Wed, 19 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 787999 | 967033 | — | Sale at price 1.10 - 1.35 per share. | VERSANT VENTURE CAPITAL VI, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-08-12 00:00:00 | D |
| 1 | 35000 | 73850 | — | Purchase at price 2.11 per share. | BRADY STEPHEN R | Chief Executive Officer | — | 2024-07-03 00:00:00 | D |
| 2 | 7500 | 16200 | — | Purchase at price 2.16 per share. | TROJANOWSKI JUSTIN | Officer | — | 2024-06-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -40.14M | -27.66M | -33.45M | -26.65M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -41.84M | -29.49M | -35.71M | -28.30M |
| ReconciledDepreciation | 389.00K | 381.00K | 638.00K | 374.00K |
| EBITDA | -40.14M | -27.66M | -33.45M | -26.65M |
| EBIT | -40.53M | -28.04M | -34.09M | -27.02M |
| NetInterestIncome | 183.00K | -334.00K | -1.02M | -1.27M |
| InterestExpense | 1.32M | 1.45M | 1.62M | 1.28M |
| InterestIncome | 1.50M | 1.11M | 600.00K | 7.00K |
| NormalizedIncome | -41.84M | -29.49M | -35.71M | -28.30M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -41.84M | -29.49M | -35.71M | -28.30M |
| TotalExpenses | 42.03M | 29.16M | 34.64M | 26.99M |
| TotalOperatingIncomeAsReported | -42.03M | -29.16M | -34.64M | -26.99M |
| DilutedAverageShares | 3.38M | 1.19M | 888.95K | 291.56K |
| BasicAverageShares | 3.38M | 1.19M | 888.95K | 291.56K |
| DilutedEPS | -19.50 | -24.83 | -40.17 | -97.11 |
| BasicEPS | -19.50 | -24.83 | -40.17 | -97.11 |
| DilutedNIAvailtoComStockholders | -41.84M | -29.49M | -35.71M | -28.30M |
| NetIncomeCommonStockholders | -41.84M | -29.49M | -35.71M | -28.30M |
| NetIncome | -41.84M | -29.49M | -35.71M | -28.30M |
| NetIncomeIncludingNoncontrollingInterests | -41.84M | -29.49M | -35.71M | -28.30M |
| NetIncomeContinuousOperations | -41.84M | -29.49M | -35.71M | -28.30M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -41.84M | -29.49M | -35.71M | -28.30M |
| OtherIncomeExpense | 15.00K | -51.00K | -41.00K | |
| OtherNonOperatingIncomeExpenses | 15.00K | -51.00K | -41.00K | |
| NetNonOperatingInterestIncomeExpense | 183.00K | -334.00K | -1.02M | -1.27M |
| InterestExpenseNonOperating | 1.32M | 1.45M | 1.62M | 1.28M |
| InterestIncomeNonOperating | 1.50M | 1.11M | 600.00K | 7.00K |
| OperatingIncome | -42.03M | -29.16M | -34.64M | -26.99M |
| OperatingExpense | 42.03M | 29.16M | 34.64M | 26.99M |
| ResearchAndDevelopment | 28.48M | 17.50M | 22.53M | 17.17M |
| SellingGeneralAndAdministration | 13.55M | 11.66M | 12.11M | 9.82M |
| GeneralAndAdministrativeExpense | 13.55M | 11.66M | 12.11M | 9.82M |
| OtherGandA | 13.55M | 11.66M | 12.11M | 9.82M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 3.38M | 1.70M | 809.12K | 531.56K |
| ShareIssued | 3.38M | 1.70M | 809.12K | 531.56K |
| TotalDebt | 15.37M | 20.66M | 22.11M | 18.54M |
| TangibleBookValue | 19.13M | 26.77M | 18.11M | 36.12M |
| InvestedCapital | 25.48M | 37.32M | 28.48M | 51.19M |
| WorkingCapital | 17.25M | 30.95M | 25.67M | 48.94M |
| NetTangibleAssets | 19.13M | 26.77M | 18.11M | 36.12M |
| CapitalLeaseObligations | 9.01M | 10.11M | 11.74M | 3.47M |
| CommonStockEquity | 19.13M | 26.77M | 18.11M | 36.12M |
| TotalCapitalization | 19.13M | 33.03M | 28.48M | 51.19M |
| TotalEquityGrossMinorityInterest | 19.13M | 26.77M | 18.11M | 36.12M |
| StockholdersEquity | 19.13M | 26.77M | 18.11M | 36.12M |
| RetainedEarnings | -207.11M | -165.26M | -135.77M | -100.06M |
| AdditionalPaidInCapital | 226.19M | 192.01M | 153.87M | 136.17M |
| CapitalStock | 44.00K | 22.00K | 11.00K | 7.00K |
| CommonStock | 44.00K | 22.00K | 11.00K | 7.00K |
| TotalLiabilitiesNetMinorityInterest | 22.36M | 24.84M | 27.98M | 37.12M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 8.14M | 15.42M | 20.70M | 17.09M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 8.14M | 15.42M | 20.70M | 17.09M |
| LongTermCapitalLeaseObligation | 8.14M | 9.16M | 10.33M | 2.03M |
| LongTermDebt | 6.26M | 10.37M | 15.07M | |
| CurrentLiabilities | 14.22M | 9.41M | 7.28M | 20.03M |
| CurrentDebtAndCapitalLeaseObligation | 7.22M | 5.24M | 1.41M | 1.44M |
| CurrentCapitalLeaseObligation | 869.00K | 952.00K | 1.41M | 1.44M |
| CurrentDebt | 6.35M | 4.29M | ||
| OtherCurrentBorrowings | 6.35M | 4.29M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.76M | 1.54M | 1.25M | 912.00K |
| PayablesAndAccruedExpenses | 5.24M | 2.63M | 4.62M | 17.67M |
| CurrentAccruedExpenses | 2.79M | 1.79M | 3.51M | 16.68M |
| InterestPayable | 59.00K | 113.00K | 97.00K | 92.00K |
| Payables | 2.45M | 845.00K | 1.11M | 991.00K |
| AccountsPayable | 2.45M | 845.00K | 1.11M | 991.00K |
| TotalAssets | 41.49M | 51.60M | 46.09M | 73.24M |
| TotalNonCurrentAssets | 10.01M | 11.24M | 13.14M | 4.28M |
| OtherNonCurrentAssets | 485.00K | 448.00K | 429.00K | 111.00K |
| NetPPE | 9.53M | 10.79M | 12.71M | 4.16M |
| AccumulatedDepreciation | -1.32M | -1.02M | -1.36M | -824.00K |
| GrossPPE | 10.85M | 11.82M | 14.07M | 4.99M |
| Leases | 201.00K | 235.00K | 882.00K | 840.00K |
| OtherProperties | 10.13M | 11.09M | 1.06M | 748.00K |
| MachineryFurnitureEquipment | 520.00K | 497.00K | 478.00K | 349.00K |
| BuildingsAndImprovements | 9.95M | 11.65M | 3.05M | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 31.47M | 40.36M | 32.95M | 68.96M |
| OtherCurrentAssets | 535.00K | 96.00K | 263.00K | 553.00K |
| PrepaidAssets | 671.00K | 1.04M | 1.01M | 1.58M |
| Receivables | 0.00 | 450.00K | 15.00M | |
| OtherReceivables | 450.00K | 15.00M | ||
| NotesReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 30.27M | 39.23M | 31.23M | 51.83M |
| CashAndCashEquivalents | 30.27M | 39.23M | 31.23M | 51.83M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -33.46M | -27.53M | -31.63M | -26.09M |
| RepaymentOfDebt | -4.40M | 0.00 | -4.74M | 0.00 |
| IssuanceOfDebt | 0.00 | 15.00M | ||
| IssuanceOfCapitalStock | 28.59M | 35.60M | 8.86M | 33.42M |
| CapitalExpenditure | -435.00K | -170.00K | -562.00K | -135.00K |
| InterestPaidSupplementalData | 1.18M | 1.25M | 1.54M | 953.00K |
| IncomeTaxPaidSupplementalData | 54.00K | 191.00K | 18.00K | |
| EndCashPosition | 30.71M | 39.67M | 31.60M | 51.83M |
| BeginningCashPosition | 39.67M | 31.60M | 51.83M | 18.82M |
| ChangesInCash | -8.96M | 8.07M | -20.23M | 33.01M |
| FinancingCashFlow | 24.50M | 35.60M | 11.40M | 59.06M |
| CashFlowFromContinuingFinancingActivities | 24.50M | 35.60M | 11.40M | 59.06M |
| NetOtherFinancingCharges | 10.53M | |||
| ProceedsFromStockOptionExercised | 307.00K | 0.00 | 7.28M | 108.00K |
| NetPreferredStockIssuance | 7.28M | 0.00 | ||
| PreferredStockIssuance | 7.28M | 0.00 | ||
| NetCommonStockIssuance | 28.59M | 35.60M | 8.86M | 33.42M |
| CommonStockIssuance | 28.59M | 35.60M | 8.86M | 33.42M |
| NetIssuancePaymentsOfDebt | -4.40M | 0.00 | -4.74M | 15.00M |
| NetLongTermDebtIssuance | -4.40M | 0.00 | -4.74M | 15.00M |
| LongTermDebtPayments | -4.40M | 0.00 | -4.74M | 0.00 |
| LongTermDebtIssuance | 0.00 | 15.00M | ||
| InvestingCashFlow | -435.00K | -170.00K | -562.00K | -97.00K |
| CashFlowFromContinuingInvestingActivities | -435.00K | -170.00K | -562.00K | -97.00K |
| NetOtherInvestingChanges | 38.00K | |||
| NetPPEPurchaseAndSale | -435.00K | -170.00K | -562.00K | -135.00K |
| PurchaseOfPPE | -435.00K | -170.00K | -562.00K | -135.00K |
| OperatingCashFlow | -33.03M | -27.36M | -31.07M | -25.96M |
| CashFlowFromContinuingOperatingActivities | -33.03M | -27.36M | -31.07M | -25.96M |
| ChangeInWorkingCapital | 1.61M | -2.68M | 868.00K | -613.00K |
| ChangeInOtherCurrentLiabilities | -1.10M | -1.63M | -1.50M | -1.04M |
| ChangeInPayablesAndAccruedExpense | 2.82M | -1.24M | 1.45M | 606.00K |
| ChangeInAccruedExpense | 1.22M | -976.00K | 1.45M | 815.00K |
| ChangeInInterestPayable | -54.00K | 16.00K | -256.00K | 92.00K |
| ChangeInPayable | 1.60M | -263.00K | 1.00K | -209.00K |
| ChangeInAccountPayable | 1.60M | -263.00K | 1.00K | -209.00K |
| ChangeInPrepaidAssets | -110.00K | 193.00K | 915.00K | -179.00K |
| OtherNonCashItems | 1.51M | 1.88M | 1.57M | 1.48M |
| StockBasedCompensation | 5.30M | 2.55M | 1.56M | 1.10M |
| DepreciationAmortizationDepletion | 389.00K | 381.00K | 638.00K | 374.00K |
| DepreciationAndAmortization | 389.00K | 381.00K | 638.00K | 374.00K |
| Depreciation | 389.00K | 381.00K | 638.00K | 374.00K |
| NetIncomeFromContinuingOperations | -41.84M | -29.49M | -35.71M | -28.30M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TPST
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|